On November 29, 2022 Candel Therapeutics, Inc. ("Candel" or "the Company") (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, reported it will host a virtual Research and Development (R&D) Day from 11:00 am – 1:30 pm ET on Tuesday, December 6, 2022 (Press release, Candel Therapeutics, NOV 29, 2022, View Source [SID1234624539]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Candel’s first R&D Day will include presentations from its executive leadership, clinical investigators, scientific advisors, and key collaborators. The event will provide an extensive overview of the Company’s viral immunotherapy approach and oncology-focused pipeline, with new data being presented from its phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with stage III/IV non-small cell lung cancer (NSCLC). The event will conclude with an interactive Q&A session. Click here to register for the event.
The event will include the following presenters:
Introduction to Candel Therapeutics
Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, Candel Therapeutics
Intratumor viral immunotherapy: a new approach to induce systemic anti-tumor immunity
James P. Allison, PhD, Regental Professor and Chair of the Department of Immunology, MD Anderson Cancer Center and Director, Parker Institute for Cancer Research
Clinical perspective on viral immunotherapy
Padmanee Sharma, MD, PhD, Professor of Genitourinary Medical Oncology and Immunology, MD Anderson Cancer Center
Phase 2 clinical trial of CAN-2409 treatment in NSCLC
Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
Daniel H. Sterman, MD, Professor and Director, Pulmonary, Critical Care and Sleep Medicine, NYU Langone Health
Roy Herbst, MD, PhD, Ensign Professor of Medicine, Professor of Pharmacology and Chief of Medical Oncology, Yale Cancer Center
Phase 1 clinical trial of CAN-2409 combined with nivolumab and standard of care in first-line treatment with high-grade glioma
Patrick Y. Wen, MD, Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute and Professor, Neurology, Harvard Medical School
Phase 1 clinical trial of CAN-3110 in recurrent high-grade glioma
E. Antonio Chiocca, MD, PhD, Chair, Department of Neurosurgery, Brigham and Women’s Hospital and Professor, Harvard Medical School
The enLIGHTEN Discovery Platform
Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics
UPenn – Candel discovery partnership: Combination therapy to overcome CAR-T resistance in solid tumors
Carl H. June, MD, Richard W. Vague Professor in Immunotherapy and Director, Center for Cellular Immunotherapies and Parker Institute for Cancer Therapy, Perelman School of Medicine, University of Pennsylvania
Neil C. Sheppard, DPhil, Adjunct Associate Professor of Pathology and Laboratory Medicine, Head of the T Cell Engineering Lab, and Director for Research Technologies and Innovation, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania
Interactive Q&A
Registration for this virtual event and access to the live webcast and subsequent replay will be accessible under "Events and Presentations" on the Investors page of the Company’s website at View Source or by clicking here.